The temporal findings support continued surveillance throughout therapy but do not establish a phase-specific monitoring strategy, and Ibrutinib was associated with substantial toxicity and frequent treatment modification in routine clinical practice.
Abstract
Background Ibrutinib is widely used in B-cell malignancies, yet real-world safety data remain heterogeneous, particularly in underrepresented regional populations. Objective To characterize the adverse-event profile and severity and explore factors associated with Grade 3–5 toxicity and permanent treatment discontinuation among patients receiving ibrutinib in routine clinical practice. Methods A retrospective cohort study was conducted at King Abdullah Medical City, Makkah, Saudi Arabia, with follow-up through December 2025. Adult patients with B-cell malignancies who received ibrutinib and had sufficient clinical documentation for safety-outcome ascertainment were included. The primary endpoint was the occurrence of at least one Grade 3–5 adverse event according to CTCAE v5.0. Secondary outcomes included dose modifications, permanent treatment discontinuation, factors associated with toxicity, and temporal adverse-event patterns. Results Among 57 patients, all 57 (100%) experienced at least one adverse event and 41 (71.9%) experienced at least one Grade 3–5 adverse event. Neutropenia and hypertension were the most frequent severe toxicities. Dose modification occurred in 47 patients (82.5%), and permanent discontinuation occurred in 17 (29.8%). In reduced Firth penalized-likelihood models adjusted for starting-dose category, pre-existing ischemic heart disease was associated with permanent discontinuation (aOR 6.25, 95% profile-likelihood CI 1.29–39.19; p = 0.023), while creatinine clearance <60 mL/min was associated with Grade 3–5 toxicity (aOR 5.53, 95% profile-likelihood CI 1.26–38.46; p = 0.022). A patient-level omnibus permutation test indicated a difference in adverse-event cluster distributions between the early (≤90 days) and late (>90 days) periods (p = 0.004), although an equal-window sensitivity analysis comparing days 0–90 with days 91–180 was not significant (p = 0.240). Conclusion Ibrutinib was associated with substantial toxicity and frequent treatment modification in routine clinical practice. Pre-existing ischemic heart disease and impaired renal function emerged as exploratory markers of treatment vulnerability. The temporal findings support continued surveillance throughout therapy but do not establish a phase-specific monitoring strategy.
Background and aim This retrospective cohort study aimed to characterize the real-world clinical outcomes and treatment-emergent adverse events (TEAEs) of anlotinib-containing regimens among pediatric patients with solid tumors treated at the Children’s Hospital of Zhejiang University School of Medicine from January 20...
Qiao Hua, Zhou Xia, Ya-Qing Gu et al.· Frontiers in Oncology· 0 citations
Venetoclax plus azacitidine improves survival in older or unfit patients with newly diagnosed acute myeloid leukemia (AML), as demonstrated in the VIALE‐A trial. 2 However, real‐world data in hospitalized patients—particularly those with secondary AML or adverse‐risk mutations—remain limited. We conducted a retrospecti...
M. Pane, D. Bandi, Andrew Whiteley et al.· Advances in Hematology· 0 citations
Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs). Data regarding immunotherapy safety in elderly patients remain limited. This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients...
Introduction: Abemaciclib combined with endocrine therapy is an established adjuvant treatment for high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. However, its prolonged use (up to two years) poses challenges related to tolerability and adherence,...
R. Bonadio, L. Holland, C. Cavalcanti et al.· Mastology· 0 citations
466
Background:
Treatment-related adverse events (TRAEs) are a common cause of discontinuation in cancer clinical trials. Although TRAEs are routinely documented, the relative contributions of patients (pts), clinicians, and protocol-mandated requirements to these decisions remain poorly characterized. We sough...
Hannah Pearl, Breanna Yi-Zhu Yang, Jacob Abrahams et al.· JCO Oncology Practice· 0 citations
Cancer of unknown primary (CUP) remains a challenging malignancy with a poor prognosis. Although immune checkpoint inhibitors have shown activity in CUP, available data remains limited. We describe clinical outcomes and a comprehensive biomarker analysis from an expanded access trial of nivolumab in CUP. Patients with...
J. Tanizaki, K. Yonemori, Yuichi Takiguchi et al.· International Journal of Cli...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.